Vaccination against malaria: Recent advances and the problems of antigenic diversity and other parasite evasion mechanisms

  • Howard R
  • 5


    Mendeley users who have this article in their library.
  • 13


    Citations of this article.


Due to the complexity of the malaria life cycle and the stage-specificity of immunity, a malaria vaccine will most likely be multicomponent, directed against surface epitopes on sporozoites, infected erythrocytes, merozoites and gametes. The CSP antigen of sporozoites is best understood at the structural and immunochemical level and vaccine trials employing peptides derived from this protein are currently underway. To date, no antigenic diversity of the immunodominant repeat epitope of the CSP protein has been uncovered in natural isolates of P. falciparum, raising optimism for eventual applicability of the laboratory trials to a field vaccine. Numerous surface antigens on merozoites and gametes have been identified with monoclonal antibodies and shown to be potential vaccine targets based on in vitro and in vivo studies with these antibodies. The problem of antigenic diversity and parasite lability seems acute in the asexual blood stages, and perhaps also with transmission-blocking antigens of gametes. Ways must be found to identify invariant surface epitopes that are so critical to parasite survival that in the face of a potentially lethal immune response mutant organisms cannot alter the target epitope and evade destruction. © 1986.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Russell J. Howard

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free